Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study

This exploratory phase II study evaluated the safety and efficacy of belatacept in de novo adult liver transplant recipients. Patients were randomized (N = 260) to one of the following immunosuppressive regimens: (i) basiliximab + belatacept high dose [HD] + mycophenolate mofetil (MMF), (ii) belatac...

Descripción completa

Detalles Bibliográficos
Autores principales: Klintmalm, G B, Feng, S, Lake, J R, Vargas, H E, Wekerle, T, Agnes, S, Brown, K A, Nashan, B, Rostaing, L, Meadows-Shropshire, S, Agarwal, M, Harler, M B, García-Valdecasas, J-C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140547/
https://www.ncbi.nlm.nih.gov/pubmed/25041339
http://dx.doi.org/10.1111/ajt.12810

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140547/
https://www.ncbi.nlm.nih.gov/pubmed/25041339
http://dx.doi.org/10.1111/ajt.12810

Ejemplares similares